UBS AM’s Pfizer PFE Stock Holding History

UBS AM’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$969M	Sell	34,522,932 -1,190,103	-3%	-$31.7M	0.2%	91
2025 Q4	$889M	Buy	35,713,035 +1,517,551	+4%	+$38.3M	0.19%	95
2025 Q3	$871M	Sell	34,195,484 -9,682,206	-22%	-$239M	0.19%	102
2025 Q2	$1.06B	Buy	43,877,690 +5,186,998	+13%	+$121M	0.22%	98
2025 Q1	$980M	Sell	38,690,692 -711,927	-2%	-$18.6M	0.25%	86
2024 Q4	$1.05B	Buy	39,402,619 +1,333,740	+4%	+$36.2M	0.24%	75
2024 Q3	$1.1B	Buy	38,068,879 +6,977,587	+22%	+$204M	0.28%	66
2024 Q2	$870M	Buy	31,091,292 +6,233,161	+25%	+$172M	0.25%	72
2024 Q1	$690M	Sell	24,858,131 -865,726	-3%	-$24M	0.25%	73
2023 Q4	$741M	Sell	25,723,857 -968,657	-4%	-$29.3M	0.29%	64
2023 Q3	$885M	Buy	26,692,514 +1,817,203	+7%	+$64.3M	0.4%	43
2023 Q2	$1.01B	Hold	24,875,311	–	–	0.49%	34
2023 Q1	$1.01B	Sell	24,875,311 -3,117,981	-11%	-$135M	0.49%	34
2022 Q4	$1.43B	Buy	27,993,292 +3,147,768	+13%	+$151M	0.75%	20
2022 Q3	$1.09B	Sell	24,845,524 -1,134,047	-4%	-$55.1M	0.61%	24
2022 Q2	$1.36B	Buy	25,979,571 +1,820,095	+8%	+$92.8M	0.71%	18
2022 Q1	$1.25B	Sell	24,159,476 -139,992	-0.6%	-$7.26M	0.54%	27
2021 Q4	$1.43B	Buy	24,299,468 +570,667	+2%	+$28.3M	0.55%	23
2021 Q3	$1.02B	Buy	23,728,801 +457,513	+2%	+$20.3M	0.42%	42
2021 Q2	$911M	Buy	23,271,288 +1,432,656	+7%	+$55.7M	0.39%	47
2021 Q1	$791M	Buy	21,838,632 +1,007,711	+5%	+$35.8M	0.35%	53
2020 Q4	$767M	Sell	20,830,921 -836,784	-4%	-$30.7M	0.36%	49
2020 Q3	$754M	Sell	21,667,705 -2,363,316	-10%	-$82.9M	0.41%	45
2020 Q2	$746M	Sell	24,031,021 -366,355	-2%	-$12.4M	0.46%	39
2020 Q1	$756M	Buy	24,397,376 +2,543,438	+12%	+$86.7M	0.54%	33
2019 Q4	$812M	Buy	21,853,938 +181,414	+0.8%	+$6.46M	0.5%	37
2019 Q3	$739M	Sell	21,672,524 -704,173	-3%	-$25.6M	0.5%	37
2019 Q2	$920M	Sell	22,376,697 -345,375	-2%	-$13.7M	0.66%	24
2019 Q1	$916M	Buy	22,722,072 +321,145	+1%	+$12.9M	0.68%	20
2018 Q4	$928M	Buy	22,400,927 +268,786	+1%	+$11.2M	0.8%	17
2018 Q3	$925M	Sell	22,132,141 -595,286	-3%	-$22.9M	0.69%	21
2018 Q2	$782M	Sell	22,727,427 -186,217	-0.8%	-$6.36M	0.6%	26
2018 Q1	$772M	Buy	22,913,644 +1,932,833	+9%	+$66.4M	0.61%	24
2017 Q4	$721M	Buy	20,980,811 +164,363	+0.8%	+$5.6M	0.61%	26
2017 Q3	$705M	Buy	20,816,448 +275,394	+1%	+$8.85M	0.64%	27
2017 Q2	$655M	Buy	20,541,054 +1,000,161	+5%	+$31.5M	0.63%	25
2017 Q1	$634M	Buy	19,540,893 +1,574,612	+9%	+$49.6M	0.65%	24
2016 Q4	$554M	Sell	17,966,281 -426,206	-2%	-$13M	0.62%	26
2016 Q3	$591M	Buy	18,392,487 +810,677	+5%	+$27.1M	0.64%	24
2016 Q2	$587M	Buy	17,581,810 +1,672	+0%	+$53.4K	0.66%	24
2016 Q1	$494M	Sell	17,580,138 -4,287,723	-20%	-$122M	0.57%	31
2015 Q4	$670M	Sell	21,867,861 -3,721,647	-15%	-$117M	0.76%	17
2015 Q3	$763M	Sell	25,589,508 -2,979,110	-10%	-$95.5M	0.84%	16
2015 Q2	$909M	Buy	28,568,618 +4,266,856	+18%	+$139M	0.87%	13
2015 Q1	$802M	Sell	24,301,762 -1,677,028	-6%	-$53.3M	0.77%	17
2014 Q4	$768M	Buy	25,978,790 +141,417	+0.5%	+$4.05M	0.73%	22
2014 Q3	$725M	Buy	25,837,373 +484,313	+2%	+$13.6M	0.72%	19
2014 Q2	$714M	Sell	25,353,060 -113,534	-0.4%	-$3.24M	0.72%	17
2014 Q1	$776M	Buy	25,466,594 +1,878,260	+8%	+$56M	0.83%	13
2013 Q4	$685M	Buy	23,588,334 +31,729	+0.1%	+$923K	0.78%	15
2013 Q3	$642M	Sell	23,556,605 -1,993	-0%	-$54.2K	0.79%	14
2013 Q2	$626M	Buy	+23,558,598	New	+$651M	0.81%	19

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

UBS AM's PFE Position: Q1 2026 in Review

UBS AM reduced its Pfizer (PFE) stake by 3.3% in Q1 2026, selling an estimated $31.7M and leaving 34,522,932 shares worth $969M. The position accounts for 0.2% of the portfolio, ranked #91.

UBS AM first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.43B in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

UBS AM held 34,522,932 shares of Pfizer worth $969M as of Q1 2026.
UBS AM sold 1,190,103 Pfizer shares in Q1 2026, an estimated $31.7M.
Pfizer made up 0.2% of UBS AM's portfolio in Q1 2026, its #91 holding.
UBS AM first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
UBS AM's Pfizer position peaked at $1.43B in Q4 2021.
2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.